In focus
OncoC4's Cesalatamig Shows 33% Response Rate in Pretreated NSCLC at SITC 2026
OncoC4 reported Phase 1/2 results for cesalatamig monotherapy in PD-(L)1-resistant/refractory NSCLC, with a 33% objective response rate and 90% disease control rate at 10 mg/kg every three weeks. The data were presented at the SITC 2026 Annual Meeting in Phoenix.
Read the story